0.0950
0.0000
(0.00%)
As of December 13 at 3:11:37 PM EST. Market Open.
Breakdown
TTM
1/31/2024
1/31/2023
1/31/2022
1/31/2021
Total Revenue
57.1610
87.3730
--
236.0370
--
Cost of Revenue
--
--
3,050.0280
512.8700
--
Gross Profit
--
--
-1,554.6850
-276.8330
--
Operating Expense
2,477.9900
4,013.8660
5,277.6750
9,517.1390
630.2260
Operating Income
-2,420.8290
-3,926.4930
-5,277.6750
-9,793.9720
-630.2260
Net Non Operating Interest Income Expense
6.5610
87.6680
305.7880
-205.4260
-9.8240
Other Income Expense
-183.0860
167.7500
14.9280
-6,472.3170
-466.3450
Pretax Income
-2,597.3540
-3,671.0750
-4,956.9590
-16,471.7150
-1,106.3950
Net Income Common Stockholders
-2,398.2140
-5,102.7040
-9,651.5670
-15,945.8450
-1,106.3950
Diluted NI Available to Com Stockholders
-2,398.2140
-5,102.7040
-9,651.5670
-15,945.8450
-1,106.3950
Basic EPS
-0.07
-0.18
-0.39
-0.73
-0.05
Diluted EPS
-0.07
-0.18
-0.39
-0.73
-0.05
Basic Average Shares
38,036.1840
29,067.7040
25,202.5760
21,962.2370
24,485.2240
Diluted Average Shares
38,036.1840
29,067.7040
25,202.5760
21,962.2370
24,485.2240
Total Expenses
2,477.9900
4,013.8660
5,277.6750
10,030.0090
630.2260
Net Income from Continuing & Discontinued Operation
-2,398.2140
-5,102.7040
-9,651.5670
-15,945.8450
-1,106.3950
Normalized Income
-2,233.6910
-3,838.8250
-4,974.2610
-9,463.1780
-640.0500
Interest Income
--
87.6680
305.7880
--
--
Interest Expense
--
--
266.5160
205.4260
9.8240
Net Interest Income
6.5610
87.6680
305.7880
-205.4260
-9.8240
EBIT
-2,420.8290
-3,926.4930
-5,277.6750
-16,266.2890
-1,096.5710
EBITDA
-2,402.2000
-3,908.1970
-5,263.2640
-16,084.8770
-1,083.6470
Reconciled Cost of Revenue
--
--
3,050.0280
512.8690
--
Reconciled Depreciation
18.6280
18.2940
14.0530
181.4120
12.9240
Net Income from Continuing Operation Net Minority Interest
-2,688.5290
-3,671.0750
-4,956.9590
-15,945.8450
-1,106.3950
Total Unusual Items Excluding Goodwill
-454.8380
167.7500
17.3020
-6,482.6670
-466.3450
Total Unusual Items
-454.8380
167.7500
17.3020
-6,482.6670
-466.3450
Normalized EBITDA
-1,947.3620
-4,075.9470
-5,280.5660
-9,602.2100
-617.3020
1/31/2021 - 6/23/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MOOD.CN Doseology Sciences Inc.
0.1200
0.00%
FUM.L Futura Medical plc
16.96
+2.79%
CYBN.NE Cybin Inc.
14.30
-0.90%
ATNM Actinium Pharmaceuticals, Inc.
1.1650
-4.51%
RGLS Regulus Therapeutics Inc.
1.0300
+3.00%
ATAI Atai Life Sciences N.V.
1.5400
-3.75%
MNMD Mind Medicine (MindMed) Inc.
6.89
-3.44%
JAZZ Jazz Pharmaceuticals plc
125.37
+0.26%
GNLX Genelux Corporation
4.0300
+2.54%
CABA Cabaletta Bio, Inc.
2.2950
-1.92%